Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 14, 2009; 15(30): 3734-3743
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3734
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3734
Table 1 Differences in toxicity of the standard treatments for colorectal cancer between whites and AAs
Regimens | Toxicity |
Irinotecan and oxaliplatin | FOLFIRI, FOLFOX and IROX are less toxic to AAs than Whites |
Fluoropyrimidines | 5-FU is less toxic to AAs than Whites |
Cetuximab | Whites are more prone to hypersensitivity reactions |
Table 2 Differences in toxicity of the standard treatments for colorectal cancer between Whites and African Americans
Regimens | Toxicity | Difference | Reference |
Irinotecan and oxaliplatin | FOLFIRI, FOLFOX and IROX are less toxic to AAs than Whites | 34% vs 48%, P = 0.004, for severe toxicity | [95] |
5% vs 17%, P = 0.004 for diarrhea | |||
Fluoropyrimidines | 5-FU regimens in the adjuvant setting differed between AA and Whites, with AA experiencing statistically significantly lower rates | Diarrhea (P < 0.001) | [98] |
Nausea (P < 0.001) | |||
Vomiting (P = 0.01) | |||
Stomatitis (P < 0.001) | |||
Overall toxicity (P = 0.005) | |||
DPD deficiency | AA, particularly AA women, have significantly reduced DPD enzyme activity compared with Whites, which may predispose this population to less 5-FU toxicity | - | [99] |
Cetuximab | In a retrospective analysis, it was shown race was strongly associated with HSR to cetuximab among patients with CRC and head and neck cancer, with Whites experiencing HSR more frequently than AA | (Fisher exact) P = 0.017 | [100] |
- Citation: Dimou A, Syrigos KN, Saif MW. Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis. World J Gastroenterol 2009; 15(30): 3734-3743
- URL: https://www.wjgnet.com/1007-9327/full/v15/i30/3734.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3734